Physician profile
Mark Beard
NPI 1013010081
$694.39
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $86.85 · 2021: $68.50 · 2022: $166 · 2023: $194 · 2024: $38.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $112.57 | 2023 | |
| Novo Nordisk INC | $64.08 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $62.09 | 2022-2023 | Austedo |
| Sanofi-Aventis U.S. LLC | $55.17 | 2019-2022 | |
| Amgen INC. | $50.19 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.65 | 2022 | |
| Lilly USA, LLC | $34.40 | 2019-2020 | |
| Daiichi Sankyo INC. | $32.98 | 2022-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $25.26 | 2019-2023 | Vaxneuvance, Gardasil 9, M-M-R II |
| Pfizer INC. | $23.07 | 2019 | |
| Pinnacle, INC | $22.78 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $22.59 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $18.93 | 2019 | |
| Abbott Laboratories | $17.52 | 2021 | |
| Abbvie INC. | $17.22 | 2023 | Viberzi, Linzess |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $16.58 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.02 | 2024 | Eliquis |
| Mylan Specialty L.P. | $14.89 | 2023 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $14.81 | 2022 | |
| Glaxosmithkline, LLC. | $12.03 | 2022 | |
| Allergan, INC. | $11.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.